welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
recruiting

A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

key information

study id #: NCT04371666

condition: Duchenne Muscular Dystrophy

status: recruiting

purpose:

To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).

intervention: Pamrevlumab, Placebo

mechanism of action: Fibrosis preventor to support muscle

results: https://clinicaltrials.gov/ct2/show/results/NCT04371666?view=results

last updated: July 19, 2020